PFS
FIG 1. · Panel A
Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruiz-Borrego, Eva María Ciruelos, Montserrat Muñoz, Mireia Margelí, Begoña Bermejo, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, José Luis Alonso-Romero, José Ángel García-Saenz, Pedro Sánchez-Rovira, Elena Álvarez, José Ignacio Chacón, Santiago González-Santiago, César A Rodríguez, Sonia Servitja, Adam D Pfefferle, Jesús Herranz, Yuan Liu, Lisa A Carey, Isabel Romero-Camarero, Rosalía Caballero, Ángel Guerrero-Zotano, Charles M Perou, Miguel Martín
JCO Precis Oncol 9 e2400937
PURPOSE: For hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard of care. They are also used after progression on first-line aromatase inhibitors (AIs), but some patients may respond better to chemotherapy-based options. We examined tumor features associated with survival from GEICAM/2013-02 PEARL, a phase III trial of palbociclib + ET versus capecitabine in AI-resistant HR+/HER2- MBC. METHODS: For 158 and 155 patients from each arm, 878 previously published gene expression signatures were derived using RNA sequencing on pretreatment tumor specimens, both primary and metastatic. Multivariable Cox models for progression-free survival (PFS) and overall survival (OS) were constructed with 16 preselected signatures related to proliferation, loss of retinoblastoma, and immune infiltration, and via Elastic Net using all signatures. RESULTS: Significant PFS difference by PAM50 intrinsic subtype was observed with palbociclib + ET. Comparing treatment arms, luminal A subtype trended toward longer PFS with palbociclib + ET, and luminal B and nonluminal subtypes had significantly longer PFS with capecitabine. Three B-cell (B-lymphocyte)-associated signatures correlated with shorter OS with palbociclib + ET. The immune-activated Immune1 TCGA breast cancer signature had significant treatment arm interaction for OS. Elastic Net iteratively selected B-cell-associated signatures independently associated with shorter OS with palbociclib + ET. CONCLUSION: PAM50 intrinsic subtype predicted PFS differences between palbociclib + ET and capecitabine. Lower B-cell-associated gene expression predicted longer OS with palbociclib + ET versus capecitabine. These features may help identify HR+/HER2- tumors resistant to further ET-based treatment with CDK4/6i.
2 个 Figure · 5 个 KM 面板
FIG 1. PAM50 intrinsic subtype correlations with PFS and OS for each treatment arm. (A) Kaplan-Meier plot of PFS with palbociclib + ET by PAM50 luminal status. (B) Kaplan-Meier plot of PFS with capecitabine by PAM50 luminal status. (C) Kaplan-Meier plot of OS with palbociclib + ET by PAM50 luminal status. (D) Kaplan-Meier plot of OS with capecitabine by PAM50 luminal status. (E) Forest plot of PAM50 intrinsic subtype correlation with PFS between treatment arms. HRs compare PFS between treatment arms by PAM50 intrinsic subtype. Luminal B and nonluminal subtypes were significantly associated with longer PFS with capecitabine than with palbociclib + ET. ET, endocrine therapy; HR, hazard ratio; LumA, Luminal A; LumB, Luminal B; mOS, median overall survival; mPFS, median progression-free survival; Nonlum, Nonluminal; OS, overall survival; PFS, progression-free survival.
FIG 1. · Panel A
Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel B
Panel B 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel C
Panel C 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel D
Panel D 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. Kaplan-Meier plot of OS for patients treated with palbociclib + ET versus capecitabine by Immune1 TCGA breast cancer (TCGA_BRCA_1198_Immune1) signature expression. Survival curves are separated by low or high tumor expression (with respect to the median; solid or dotted) of the Immune1 TCGA breast cancer signature, and by treatment with palbociclib + ET or capecitabine (blue or red). ET, endocrine therapy; OS, overall survival; TCGA, The Cancer Genome Atlas.
FIG 4. · Panel OS
Panel OS 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。